Yusuf A Rajabally
Overview
Explore the profile of Yusuf A Rajabally including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
1351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajabally Y, Min Y
Clin Neurol Neurosurg
. 2025 Jan;
249:108719.
PMID: 39798331
Diabetic polyneuropathy is the common neuropathy of diabetes. However, several inflammatory neuropathies may occur during diabetes. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represents the most treatable example. There has been uncertainty...
2.
Min Y, Visentin A, Briani C, Rajabally Y
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39658134
Antimyelin-associated glycoprotein (MAG) neuropathy is a rare autoimmune demyelinating peripheral neuropathy caused by IgM autoantibodies targeting MAG. The typical presentation is that of a slowly progressive, distal, length-dependent, predominantly sensory,...
3.
Min Y, Jeon J, Kim S, Hong Y, Englezou C, Sung J, et al.
Eur J Neurol
. 2024 Dec;
32(1):e16575.
PMID: 39654304
Background: Despite standard-of-care treatment, therapeutic outcomes in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are often incomplete. We aimed to evaluate the impact of clinical and therapeutic factors on long-term disability in...
4.
Michael M, Wieske L, Allen J, Lunn M, Doppler K, Tan C, et al.
BMC Neurol
. 2024 Oct;
24(1):415.
PMID: 39455929
Background: INCbase is an international, multicenter prospective observational study using a customizable web-based modular registry to study the clinical, biological and electrophysiological variation and boundaries of chronic inflammatory demyelinating polyneuropathy...
5.
Min Y, Hong Y, Rajabally Y, Sung J
Muscle Nerve
. 2024 Oct;
70(6):1215-1222.
PMID: 39360628
Introduction/aims: Despite treatment, a considerable proportion of patients with Guillain-Barré syndrome (GBS) experience poor recovery, highlighting a therapeutic need. There is a lack of evidence that treatment timing affects recovery....
6.
7.
8.
Rajabally Y, Min Y, Nazeer K, Englezou C
Eur J Neurol
. 2024 Jul;
31(10):e16399.
PMID: 38980202
Background And Purpose: The amplitude, timing, and determinants of improvement with available treatments are uncertain in chronic inflammatory demyelinating polyneuropathy (CIDP). Our primary objective was to quantify categorized outcomes with...
9.
Arends S, Drenthen J, de Koning L, Van den Bergh P, Hadden R, Kuwabara S, et al.
Eur J Neurol
. 2024 Jul;
31(9):e16335.
PMID: 38965709
Background And Purpose: Various electrodiagnostic criteria have been developed in Guillain-Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from...
10.
Rajabally Y
Immunotargets Ther
. 2024 Mar;
13:99-110.
PMID: 38435981
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable autoimmune disorder, for which different treatment options are available. Current first-line evidence-based therapies for CIDP include intravenous and subcutaneous immunoglobulins, corticosteroids and...